Combating multidrug-resistant Plasmodium falciparum malaria

FEBS Journal

Volumn 284, Issue 16, 2017, Pages 2569-2578

  Thu, Aung Myint ^a   Phyo, Aung Pyae ^a,b   Landier, Jordi ^a   Parker, Daniel M ^a   Nosten, François H ^a,b  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

antimalarial drug resistance; artemisinin resistance; malaria elimination; multidrug resistance malaria; Plasmodium falciparum

Indexed keywords

AMODIAQUINE; AMODIAQUINE PLUS ARTESUNATE; AMODIAQUINE PLUS ARTESUNATE PLUS LUMEFANTRINE; AMODIAQUINE PLUS MEFLOQUINE; ANTIMALARIAL AGENT; AQ 13; ARTEFENOMEL; ARTEMETHER PLUS BENFLUMETOL; ARTEMISININ DERIVATIVE; ARTESUNATE PLUS SULFADOXINEPYRIMETHAMINE; ATOVAQUONE; BENFLUMETOL; CHLOROQUINE; CIPARGAMIN; DIHYDROARTEMISININ PLUS PIPERAQUINE; DSM 265; FERROQUINE; IMIDAZOLOPIPERAZINE; INSECT REPELLENT; KAF 156; MALARIA VACCINE; MEFLOQUINE; OZ 439; PIPERAQUINE; PRIMAQUINE; PYRIMETHAMINE; PYRIMETHAMINE PLUS SULFADOXINE; SULFADOXINE; TRIOXALENE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIMALARIAL DRUG RESISTANCE; BIOASSAY; COMBINATION CHEMOTHERAPY; DISEASE TRANSMISSION; DRUG EFFICACY; DRUG QUALITY; DRUG SENSITIVITY; EARLY DIAGNOSIS; EARLY INTERVENTION; GEOGRAPHY; GROWTH INHIBITION; HEALTH PROGRAM; HEALTH SURVEY; HIGH RISK PATIENT; HOLISTIC CARE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MALARIA CONTROL; MALARIA FALCIPARUM; MEDIUM RISK PATIENT; MONOTHERAPY; NONHUMAN; PARASITOLOGY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMODIUM FALCIPARUM; POPULATION DISPERSAL; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RING STAGE SURVIVAL ASSAY; TREATMENT FAILURE; VECTOR CONTROL; DRUG RESISTANCE; MALARIA, FALCIPARUM; PHYSIOLOGY;

ANTIMALARIALS; DRUG RESISTANCE; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM;

EID: 85021720650     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.14127     Document Type: Review

References (60)

1. World Health Organization (2015) World malaria report 2015.
2. World Health Organization (2015) Global technical strategy for malaria 2016–2030.
3. Phyo AP, Ashley EA, Anderson TJ, Bozdech Z, Carrara VI, Sriprawat K, Nair S, White MM, Dziekan J, Ling C et al. (2016) Declining efficacy of artemisinin combination therapy against P. falciparum malaria on the Thai-Myanmar Border (2003–2013): the role of parasite genetic factors. Clin Infect Dis 63, 784–791.
4. Leang R, Taylor WR, Bouth DM, Song L, Tarning J, Char MC, Kim S, Witkowski B, Duru V, Domergue A et al. (2015) Evidence of Plasmodium falciparum malaria multidrug resistance to artemisinin and piperaquine in Western Cambodia: dihydroartemisinin-piperaquine open-label multicenter clinical assessment. Antimicrob Agents Chemother 59, 4719–4726.
5. Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, Quang HH, Farrar J, Thwaites G, White NJ et al. (2017) Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin-piperaquine in the south of Vietnam. Malar J 16, 27.
6. Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, Zhu G, Tang J, Liu Y, Wang W et al. (2017) Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med 376, 991–993.
7. Payne D (1987) Spread of chloroquine resistance in Plasmodium falciparum. Parasitol Today 3, 241–246.
8. Roper C, Pearce R, Nair S, Sharp B, Nosten F & Anderson T (2004) Intercontinental spread of pyrimethamine-resistant malaria. Science 305, 1124.
9. Trape JF, Pison G, Preziosi MP, Enel C, Desgrees du Lou A, Delaunay V, Samb B, Lagarde E, Molez JF & Simondon F (1998) Impact of chloroquine resistance on malaria mortality. C R Acad Sci III 321, 689–697.
10. Maude RJ, Pontavornpinyo W, Saralamba S, Aguas R, Yeung S, Dondorp AM, Day NP, White NJ & White LJ (2009) The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia. Malar J 8, 31.
11. Payne D (1988) Did medicated salt hasten the spread of chloroquine resistance in Plasmodium falciparum? Parasitol Today 4, 112–115.
12. Verdrager J (1995) Localized permanent epidemics: the genesis of chloroquine resistance in Plasmodium falciparum. Southeast Asian J Trop Med Public Health 26, 23–28.
13. White NJ (2004) Antimalarial drug resistance. J Clin Invest 113, 1084–1092.
14. World Health Organization (1967) Chemotherapy of Malaria. Report of a WHO Scientific Group. World Health Organization, Geneva, Switzerland, WHO Technical Report Series, No. 375.
15. White LJ, Flegg JA, Phyo AP, Wiladpai-ngern JH, Bethell D, Plowe C, Anderson T, Nkhoma S, Nair S, Tripura R et al. (2015) Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med 12, e1001823.
16. Witkowski B, Amaratunga C, Khim N, Sreng S, Chim P, Kim S, Lim P, Mao S, Sopha C, Sam B et al. (2013) Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis 13, 1043–1049.
17. Volkman SK, Herman J, Lukens AK & Hartl DL (2017) Genome-wide association studies of drug-resistance determinants. Trends Parasitol 33, 214–230.
18. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN & Ringwald P (2009) A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar J 8, 89.
19. Venkatesan M, Gadalla NB, Stepniewska K, Dahal P, Nsanzabana C, Moriera C, Price RN, Martensson A, Rosenthal PJ, Dorsey G et al. (2014) Polymorphisms in Plasmodium falciparum chloroquine resistance transporter and multidrug resistance 1 genes: parasite risk factors that affect treatment outcomes for P. falciparum malaria after artemether-lumefantrine and artesunate-amodiaquine. Am J Trop Med Hyg 91, 833–843.
20. Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, Patel R, Laing K, Looareesuwan S, White NJ et al. (2004) Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet 364, 438–447.
21. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K & Cheng Q (2000) Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob Agents Chemother 44, 2100–2108.
22. Anderson TJ, Nair S, McDew-White M, Cheeseman IH, Nkhoma S, Bilgic F, McGready R, Ashley E, Pyae Phyo A, White NJ et al. (2017) population parameters underlying an ongoing soft sweep in Southeast Asian malaria parasites. Mol Biol Evol 34, 131–144.
23. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, Sreng S, Anderson JM, Mao S, Sam B et al. (2014) Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 371, 411–423.
24. Amaratunga C, Lim P, Suon S, Sreng S, Mao S, Sopha C, Sam B, Dek D, Try V, Amato R et al. (2016) Dihydroartemisinin–piperaquine resistance in Plasmodium falciparum malaria in Cambodia: a multisite prospective cohort study. Lancet Infect Dis 16, 357–365.
25. Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, Chy S, Kim S, Ke S, Kloeung N et al. (2017) A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis 17, 174–183.
26. Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, Almagro-Garcia J, Neal AT, Sreng S, Suon S et al. (2017) Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis 17, 164–173.
27. Landier J, Parker DM, Thu AM, Carrara VI, Lwin KM, Bonnington CA, Pukrittayakamee S, Delmas G & Nosten FH (2016) The role of early detection and treatment in malaria elimination. Malar J 15, 363.
28. White NJ, Pongtavornpinyo W, Maude RJ, Saralamba S, Aguas R, Stepniewska K, Lee SJ, Dondorp AM, White LJ & Day NP (2009) Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance. Malar J 8, 253.
29. White NJ (1999) Delaying antimalarial drug resistance with combination chemotherapy. Parassitologia 41, 301–308.
30. Nosten F & White NJ (2007) Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg 77, 181–192.
31. White NJ (1999) Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond B Biol Sci 354, 739–749.
32. Bassat Q, Tanner M, Guerin PJ, Stricker K & Hamed K (2016) Combating poor-quality anti-malarial medicines: a call to action. Malar J 15, 302.
33. Bousema T & Drakeley C (2011) Epidemiology and infectivity of Plasmodium falciparum and Plasmodium vivax gametocytes in relation to malaria control and elimination. Clin Microbiol Rev 24, 377–410.
34. Bancone G, Chowwiwat N, Somsakchaicharoen R, Poodpanya L, Moo PK, Gornsawun G, Kajeechiwa L, Thwin MM, Rakthinthong S, Nosten S et al. (2016) Single low dose primaquine (0.25 mg/kg) does not cause clinically significant haemolysis in G6PD deficient subjects. PLoS ONE 11, e0151898.
35. Kim D, Fedak K & Kramer R (2012) Reduction of malaria prevalence by indoor residual spraying: a meta-regression analysis. Am J Trop Med Hyg 87, 117–124.
36. Smithuis FM, Kyaw MK, Phe UO, van der Broek I, Katterman N, Rogers C, Almeida P, Kager PA, Stepniewska K, Lubell Y et al. (2013) The effect of insecticide-treated bed nets on the incidence and prevalence of malaria in children in an area of unstable seasonal transmission in western Myanmar. Malar J 12, 363.
37. World Health Organization (2006) Indoor residual Spraying.
38. Nyunt MH, Aye KM, Kyaw KT, Han SS, Aye TT, Wai KT & Kyaw MP (2016) Challenges encountered by local health volunteers in early diagnosis and prompt treatment of malaria in Myanmar artemisinin resistance containment zones. Malar J 15, 308.
39. World Health Organization (2015) Update on artemisinin and ACT resistance.
40. Kay K, Hodel EM & Hastings IM (2015) Altering antimalarial drug regimens may dramatically enhance and restore drug effectiveness. Antimicrob Agents Chemother 59, 6419–6427.
41. Nguyen TD, Olliaro P, Dondorp AM, Baird JK, Lam HM, Farrar J, Thwaites GE, White NJ & Boni MF (2015) Optimum population-level use of artemisinin combination therapies: a modelling study. Lancet Glob Health 3, e758–e766.
42. Barnes KI & White NJ (2005) Population biology and antimalarial resistance: the transmission of antimalarial drug resistance in Plasmodium falciparum. Acta Trop 94, 230–240.
43. Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL, Abeyasinghe RR, Rodriguez MH, Maharaj R, Tanner M et al. (2010) Operational strategies to achieve and maintain malaria elimination. Lancet 376, 1592–1603.
44. Imwong M, Nguyen TN, Tripura R, Peto TJ, Lee SJ, Lwin KM, Suangkanarat P, Jeeyapant A, Vihokhern B, Wongsaen K et al. (2015) The epidemiology of subclinical malaria infections in South-East Asia: findings from cross-sectional surveys in Thailand-Myanmar border areas, Cambodia, and Vietnam. Malar J 14, 381.
45. Lindblade KA, Steinhardt L, Samuels A, Kachur SP & Slutsker L (2013) The silent threat: asymptomatic parasitemia and malaria transmission. Expert Rev Anti Infect Ther 11, 623–639.
46. World Health Organization (2014) From malaria control to malaria elimination: a manual for elimination scenario planning.
47. Tanner M, Greenwood B, Whitty CJ, Ansah EK, Price RN, Dondorp AM, von Seidlein L, Baird JK, Beeson JG, Fowkes FJ et al. (2015) Malaria eradication and elimination: views on how to translate a vision into reality. BMC Med 13, 167.
48. Parker DM, Landier J, von Seidlein L, Dondorp A, White L, Hanboonkunupakarn B, Maude RJ & Nosten FH (2016) Limitations of malaria reactive case detection in an area of low and unstable transmission on the Myanmar-Thailand border. Malar J 15, 571.
49. Hustedt J, Canavati SE, Rang C, Ashton RA, Khim N, Berne L, Kim S, Sovannaroth S, Ly P, Menard D et al. (2016) Reactive case-detection of malaria in Pailin Province, Western Cambodia: lessons from a year-long evaluation in a pre-elimination setting. Malar J 15, 132.
50. Imwong M, Stepniewska K, Tripura R, Peto TJ, Lwin KM, Vihokhern B, Wongsaen K, von Seidlein L, Dhorda M, Snounou G et al. (2016) Numerical distributions of parasite densities during asymptomatic malaria. J Infect Dis 213, 1322–1329.
51. Perera RS, Ding XC, Tully F, Oliver J, Bright N, Bell D, Chiodini PL, Gonzalez IJ & Polley SD (2017) Development and clinical performance of high throughput loop-mediated isothermal amplification for detection of malaria. PLoS ONE 12, e0171126.
52. Rts SCTP (2015) Efficacy and safety of RTS, S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45.
53. Olliaro P, Nevill C, LeBras J, Ringwald P, Mussano P, Garner P & Brasseur P (1996) Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 348, 1196–1201.
54. Iyer JK, Milhous WK, Cortese JF, Kublin JG & Plowe CV (2001) Plasmodium falciparum cross-resistance between trimethoprim and pyrimethamine. Lancet 358, 1066–1067.
55. Nosten F & Brasseur P (2002) Combination therapy for malaria: the way forward? Drugs 62, 1315–1329.
56. Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, Duparc S, Macintyre F, Baker M & Mohrle JJ (2016) Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis 16, 61–69.
57. White NJ (2016) Can new treatment developments combat resistance in malaria? Expert Opin Pharmacother 17, 1303–1307.
58. Hemingway J, Shretta R, Wells TN, Bell D, Djimde AA, Achee N & Qi G (2016) Tools and strategies for malaria control and elimination: What do we need to achieve a grand convergence in malaria? PLoS Biol 14, e1002380.
59. World Health Organization (2016) Artemisinin and artemisinin-based combination therapy resistance (Status Report).
60. Adelman CC & Norris J (2004) WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363, 1161.